US OptionsDetailed Quotes
NVAX250509C3500
- 2.99
- -1.03-25.62%
15min DelayClose May 5 16:00 ET
2.99High2.99Low
2.99Open4.02Pre Close1 Volume1 Open Interest3.50Strike Price299.00Turnover331.18%IV3.51%PremiumMay 9, 2025Expiry Date2.77Intrinsic Value100Multiplier3DDays to Expiry0.22Extrinsic Value100Contract SizeAmericanOptions Type0.9734Delta0.0297Gamma2.24Leverage Ratio-0.0150Theta0.0003Rho2.18Eff Leverage0.0004Vega
Novavax Stock Discussion
Novavax Strengthens Japan Presence: Improved Financial Terms in Takeda Partnership Boost COVID Vaccine Distribution
Novavax () issued the following update on the U.S. FDA BLA for Novavax’s COVID-19 Vaccine: “Last week, Novavax responded to the formal communication received from the U.S. Food and Drug Administration for our Biologics License Application (BLA) and our response addresses the request for a postmarketing commitment for a clinical trial. PMCs by their nature are completed after BLA approval. PMCs are not unusual with many approved drugs and/or biologics having at least one PMC or...
Good loading level.
Full FDA Approval: 10-30
Pandemic: 150-250
Whoever decided to sell at 7+ dollars, you are either crazy or just here for trade with quick profit. This ain’t some penny stock we are talking about. Hold well and you will be rewarded handsomely.
The $Nasdaq Composite Index (.IXIC.US)$ led the way higher, gaining 407.63 (2.5%) to 16,708.05, while the $S&P 500 Index (.SPX.US)$ added 88.10 ticks (1.7%) to 5,375.86.
Similarly, the $Dow Jones Industrial Average (.DJI.US)$ rose 419....
as a long term investor, this is nothing compare to the official approval, and the jackpot, next pandemic.
Novavax: "We Believe That Our Bla Is Approvable Based on Conversations With FDA, as of Our Pdufa Date on April 1 and Through Today
Bank of America believe it’s valued at 10 dollars.
New Study Reveals Novavax COVID Vaccine Cuts Side Effects Nearly in Half vs Pfizer
No comment yet